Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 50, 2011, Pages 20148-20153

  Liu, Li ^a   Cimbro, Raffaello ^a   Lusso, Paolo ^a   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cis versus trans; Env trimer structure; Envelope glycoprotein trimer; Functional complementation

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS 1 ENVELOPE GLYCOPROTEIN TRIMER; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ARTICLE; ASSAY; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PSEUDOTYPING; VIRUS INFECTION; VIRUS NEUTRALIZATION;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; GENETIC COMPLEMENTATION TEST; HIV-1; MUTATION; NEUTRALIZATION TESTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN SUBUNITS; SEQUENCE DELETION; TRANSFECTION; VIRION;

EID: 84055178652     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1104840108     Document Type: Article

References (51)

1. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280:1884-1888. (Pubitemid 28299385)
2. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444.
3. Schuitemaker H, van 't Wout AB, Lusso P (2011) Clinical significance of HIV-1 coreceptor usage. J Transl Med ≤:9.
4. Tilton JC, Doms RW (2010) Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 85:91-100.
5. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP (1997) Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 71:2779-2785. (Pubitemid 27119916)
6. Hartley O, Klasse PJ, Sattentau QJ, Moore JP (2005) V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21:171-189. (Pubitemid 40354360)
7. Pinter A (2007) Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr HIV Res 5:542-553.
8. Zolla-Pazner S, Cardozo T (2010) Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 10:527-535.
9. Cao J, et al. (1997) Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71:9808-9812. (Pubitemid 27492434)
10. Pinter A, et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78:5205-5215. (Pubitemid 38581472)
11. Krachmarov C, et al. (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79:780-790. (Pubitemid 40053861)
12. Krachmarov CP, et al. (2006) Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 80:7127-7135. (Pubitemid 44025209)
13. Stamatatos L, Cheng-Mayer C (1998) An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 72:7840-7845. (Pubitemid 28421774)
14. Salzwedel K, Berger EA (2000) Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41. Proc Natl Acad Sci USA 97:12794-12799.
15. Salzwedel K, Berger EA (2009) Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: A general property of the functional trimer. Retrovirology 6:75.
16. Mascola JR, et al. (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79:10103-10107. (Pubitemid 41098551)
17. Fenyö EM, et al. (2009) International network for comparison of HIV neutralization assays: The NeutNet report. PLoS ONE 4:e4505.
18. Gorny MK, et al. (2002) Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 76:9035-9045. (Pubitemid 34919862)
19. Gorny MK, et al. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 66:7538-7542.
20. Earl PL, et al. (1994) Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 68:3015-3026. (Pubitemid 24129751)
21. Lusso P, et al. (2005) Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79:6957-6968. (Pubitemid 40677327)
22. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
23. Zolla-Pazner S, et al. (2004) The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses 20:1254-1258. (Pubitemid 39557875)
24. Salzwedel K, Smith ED, Dey B, Berger EA (2000) Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: Soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 74:326-333. (Pubitemid 30002913)
25. Schønning K, Lund O, Lund OS, Hansen JES (1999) Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. J Virol 73:8364-8370. (Pubitemid 29441698)
26. Yang XZ, Kurteva S, Lee S, Sodroski J (2005) Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79:3500-3508. (Pubitemid 40327938)
27. Crooks ET, et al. (2008) Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377:364-378.
28. Magnus C, Regoes RR (2010) Estimating the stoichiometry of HIV neutralization. PLOS Comput Biol 6:e1000713.
29. Hu G, Liu J, Taylor KA, Roux KH (2011) Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol 85:2741-2750.
30. Stanfield RL, et al. (1999) Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure 7:131-142. (Pubitemid 29159699)
31. Poignard P, et al. (2003) Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 77:353-365. (Pubitemid 36004975)
32. Crooks ET, et al. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366:245-262. (Pubitemid 47393683)
33. Moore PL, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80:2515-2528. (Pubitemid 43271557)
34. Herrera C, et al. (2005) The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338:154-172. (Pubitemid 40835934)
35. Pancera M, Wyatt R (2005) Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332:145-156. (Pubitemid 40127236)
36. Dey AK, David KB, Lu M, Moore JP (2009) Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385:275-281.
37. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: Seeing antigens in new ways. Nat Immunol 10:573-578.
38. Zhu P, et al. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.
39. Zanetti G, Briggs JAG, Grünewald K, Sattentau QJ, Fuller SD (2006) Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2:e83.
40. Bennett A, et al. (2007) Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120. J Biol Chem 282:27754-27759. (Pubitemid 47533564)
41. Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH (2008) Cryoelectron tomography of HIV-1 envelope spikes: Further evidence for tripod-like legs. PLoS Pathog 4:e1000203.
42. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113.
43. Wu SR, et al. (2010) Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc Natl Acad Sci USA 107:18844-18849.
44. White TA, et al. (2010) Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: Strain-dependent variation in quaternary structure. PLoS Pathog 6:e1001249.
45. Chen B, et al. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841. (Pubitemid 40314887)
46. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA (2000) Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 74:1961-1972. (Pubitemid 30434055)
47. Gorny MK, et al. (2005) Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 79:5232-5237. (Pubitemid 40464273)
48. Robinson JE, et al. (2010) Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 84:3443-3453.
49. Wang W, et al. (2008) Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 153:111-119.
50. Montefiori DC (2004) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Current Protocols in Immunology, eds Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, StroberW (Wiley, New York), Suppl 64, pp 12.11.11-12.11.17.
51. Rusert P, et al. (2011) Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med 208:1419-1433.